Background. There is limited evidence that the DOTS (directly observed therapy, short course) strategy for tuberculosis (TB) control can contain the emergence and spread of drug resistance in the absence of second-line treatment. We compared drug-resistance levels between 1996 and 2001 in the south of Vietnam, an area with a well-functioning DOTS program.
With 18 million cases and 2 million deaths annually, tuberculosis (TB) is a major cause of morbidity and mortality worldwide [1] . The approach to TB control advocated by the World Health Organization (WHO) is DOTS (directly observed therapy, short course), which focuses on the treatment of sputum smear-positive pul-monary TB with standardized short-course chemotherapy under proper case-management conditions [2] .
Among the objectives of the DOTS strategy is the prevention of the emergence and spread of resistance to anti-TB drugs, in particular of resistance to both isoniazid and rifampin (multidrug resistance [MDR] ). MDR-TB carries a highly increased risk of treatment failure or death with short-course chemotherapy and is an important challenge for TB control [3] [4] [5] . An increasing number of TB control programs are adding second-line treatment of patients with MDR-TB to their DOTS services (previously called "DOTS-Plus") [6] . Although it is clear that the individual patient with MDR-TB benefit from second-line treatment [7] , it is still a matter of debate whether and under what conditions the DOTS strategy as such is effective in containing the spread of drug resistance [8] . Recently, a prospective population-based study in Mexico showed that the introduction of DOTS rapidly reduced the Downloaded from https://academic.oup.com/jid/article-abstract/194/9/1226/904869 by guest on 04 February 2019 transmission and incidence of drug-resistant TB [9] . In Botswana, however, repeated nationwide surveys showed a significan increase in the prevalence of drug resistance among new patients with TB, despite the presence of a long-standing DOTS program [10] .
Vietnam is among the countries with a high burden of TB [6] . The National Tuberculosis Control Program of Vietnam (NTPV) implemented the DOTS strategy in 1989, and the estimated case-detection rate has been 70% since 1997 [6, 11] . The NTPV's standard treatment regimen for new (i.e., previously untreated) patients consists of 2 months of streptomycin, isoniazid, rifampin, and pyrazinamide, followed by 6 months of isoniazid and ethambutol (the 2SHRZ/6HE regimen). It has been used widely since 1990, with cure rates well over 85% and failure rates !3% [11] .
Despite high performance by these indicators, there are concerns about the ability of the NTPV to control the spread of drug resistance in the absence of second-line treatment [12] . This applies in particular to the southern part of the country, which in 2002 was home to 38% of the country's population of 80 million but carried 54% of the burden of smear-positive TB [11] . In the firs nationwide drug-resistance survey conducted among new patients with smear-positive TB in 1996, this region had the highest level of drug resistance (36.1%) [13] . In particular, the levels of resistance against isoniazid (21.6%) and streptomycin (29.4%) were high, as was the level of MDR (3.5%). Subsequent studies of new patients with smear-positive TB in Ho Chi Minh City showed that 15 (65.2%) of 23 patients who experienced treatment failure during the 2SHRZ/6HE regimen developed MDR-TB and that the risk of treatment failure for those infected with strains resistant to both streptomycin and isoniazid was increased 13-fold, compared with that for those infected with pansusceptible strains [14, 15] . Moreover, the south of Vietnam has a rapidly expanding private health sector, in particular in the large urban area of Ho Chi Minh City. It has been estimated that 30%-40% of all TB cases in Ho Chi Minh City are treated in the private sector [16] , with low cure rates [17, 18] .
As part of the WHO/International Union against Tuberculosis and Lung Disease (IUATLD) Global Project on DrugResistance Surveillance, the NTPV conducted a second nationwide survey of anti-TB drug resistance among new patients with smear-positive TB in 2001. This survey also included previously treated patients. Here, we report the results for the south of Vietnam and compare them with the results from the previous survey, to assess trends over time.
METHODS
The survey was conducted between 1 August and 31 October 2001 in 40 clusters (i.e., district TB units, general hospitals, and designated TB hospitals). These included the 22 clusters studied in the 1996 survey, which had been randomly selected in 1995 with sampling probabilities proportional to the number of notifie new patients with smear-positive TB in 1994. The 18 clusters added to these were randomly selected in 2001 with sampling probabilities proportional to the number of notifie new patients in 2000. In each cluster, 23 consecutively registered new patients with smear-positive TB were enrolled. To obtain information on the level of acquired drug resistance, each cluster was requested to also submit sputum specimens from each consecutive patient with smear-positive TB who had a history of TB treatment for 1 month or more and had received their diagnosis during the period in which the new patients were included. This was expected to be 4 patients/ cluster, on average. Among the clusters selected for the firs survey were 3 that had each been administratively split into 2 clusters since the firs survey was conducted but were inadvertently treated as multiple clusters in the data-collection process. In the analysis, these were treated as single clusters, with consequently larger numbers of patients.
Two sputum specimens were collected from each patient and sent, without the addition of decontaminant, to the Regional Mycobacterial Reference Laboratory (RMRL) in Ho Chi Minh City within 4 days. Treatment history and symptoms were ascertained by clinic staff from treatment registers and by interviewing the patient by means of a standard questionnaire.
At the RMRL, specimens were decontaminated and homogenized with 4% NaOH, inoculated onto modifie Ogawa medium by the Petroff method, and incubated at 35ЊC-37ЊC for up to 4-8 weeks [19] . Cultures were examined for growth at the end of weeks 1, 2, 4, 6, and 8 after inoculation; cultures with no growth after 8 weeks were reported as negative. Mycobacterium tuberculosis was identifie by the niacin test. Drug susceptibility testing (DST) was done by the proportion method, in accordance with WHO/IUATLD guidelines [19] . Criteria for drug resistance were у1% colony growth at 28 or 40 days relative to the drug-free control medium at the following drug concentrations: for isoniazid, 0.2 mg/mL; for rifampin, 40 mg/ mL; for streptomycin, 4 mg/mL; and for ethambutol, 2 mg/mL [19] . External DST quality control was done by annual proficienc testing undertaken by the Supranational Reference Laboratory in Seoul, South Korea. Concordance in 2001 was 100% for both isoniazid and rifampin and was 93% for both streptomycin and ethambutol.
Data were double entered into EpiInfo (version 6.4; Centers for Disease Control and Prevention), and discrepancies were checked against the raw data. Data were analyzed in Stata (version 8; StataCorp). Isolates identifie as mycobacteria other than TB (MOTT) were excluded from the analysis.
Drug resistance among new patients was define as the presence of resistant M. tuberculosis isolates in newly diagnosed patients who either had never been treated with anti-TB drugs NOTE. Percentages shown are weighted for individual sampling probabilities. CI, confidence interval; E, ethambutol; H, isoniazid; R, rifampicin; S, streptomycin.
or had been treated for !1 month. Drug resistance among previously treated patients was define as that found in patients with a history of a least 1 month of anti-TB therapy. Multidrug resistance was define as resistance to at least isoniazid and rifampin [19] .
The prevalence of drug resistance was calculated as the proportion across all clusters after weighting for the exact sampling probabilities for each individual patient for whom DST results were available. Although the sampling scheme was intended to be self-weighting, this weighed analysis was preferred for 2 reasons. First, the sampling probabilities of the clusters selected in 1994 differed from the probabilities by which these clusters would have been sampled in 2000. Second, there was large variation in the numbers of patients for whom DST results were available. The exact sampling probabilities were calculated as the cluster sampling probability times the individual sampling probability within the cluster. The cluster sampling probabilities were calculated as the cluster patient load times the number of selected clusters divided by the total patient population, using data for the year 1994 for clusters that had been selected for the firs survey and data for the year 2000 for clusters that were selected for the second survey only. Individual sampling probabilities were calculated as the number of patients for whom DST results were obtained divided by the cluster patient load in 2000. In all these analyses, confidenc intervals (CIs) and P values were adjusted for the cluster design by first order Taylor linearization and by the second-order correction of Rao and Scott of the Pearson x 2 test, respectively, as implemented by the Stata svy commands [20, 21] . Multivariate analysis was done by logistic regression. Because population weights were applied, P values were based on the Wald statistic [22] . For age group, the P values presented are for ordinal linear fitting
For comparison with the previous survey, design effects were calculated separately for the 2 surveys. Aggregation of MDR-TB cases within clusters was analyzed by assessing the intraclass coefficien r by 1-way analysis of variance [23] . 
RESULTS
During the study period, 2360 sputum specimens were collected from 1180 patients with smear-positive pulmonary TB. On the basis of an expected number of 23 new patients for each cluster, the proportion of specimens received at the RMRL was 106%. Specimens from !23 patients were received from 19 clusters (47.5%), including 4 (10.0%) with 15 or less, primarily because of insufficien numbers of patients registered during the inclusion period. Excluded were 118 patients (10%) because of either culture contamination (9 patients [1%]), negative culture result (98 patients [9%]), or growth of MOTT (11 patients [1%] ). Previous treatment status was missing for 38 patients (3%). The remaining isolates from 1024 patients (87%) underwent DST. Of 1024 strains, 888 (87%) were isolated from new patients, and 136 (13%) were isolated from previously treated patients.
The mean number of new patients per cluster was 22 (range, 5-40). Of the 888 isolates from new patients, 238 (26.3%) were resistant to at least 1 drug, 154 (16.6%) were resistant to isoniazid, 22 (2.0%) were resistant to rifampin, 12 (1.1%) were resistant to ethambutol, 173 (19.4%) were resistant to streptomycin, and 20 (1.8%) were MDR (resistant to both isoniazid and rifampin) (table 1). There were 9 clusters with 1 MDR case, 2 clusters with 2 MDR cases, 1 cluster with 3 MDR cases, and 1 cluster with 4 MDR cases.
The distribution of MDR isolates among clusters showed no significan aggregation (r p 0.03 [95% CI, 0-0.06]). Of the 20 MDR isolates, 7 (35.0%) were resistant to isoniazid, rifampin, streptomycin, and ethambutol, and 8 (40.0%) were resistant to isoniazid, rifampin, and streptomycin.
Of the 136 isolates from previously treated patients, 89 (62.9%) were resistant to at least 1 drug, 70 (52.0%) were resistant to isoniazid, 40 (26.3%) were resistant to rifampin, 15 (9.1%) were resistant to ethambutol, and 64 (38.8%) were resistant to streptomycin (table 1) . MDR was observed in 35 isolates (23.2%) and aggregated significantl within clusters ( [95% CI, 0.12-0.51]). There were 10 clusters with 1 r p 0.32 MDR case, 1 cluster with 2 MDR cases, 3 clusters with 3 MDR cases, 2 clusters with 4 MDR cases, and 1 cluster with 6 MDR cases.
Both isoniazid and streptomycin resistance in new patients was significantl more common in urban areas than in rural areas (adjusted odds ratio [aOR] for isoniazid resistance, 1.68 [95% CI, 1.14-2.47]; aOR for streptomycin resistance, 2.01 [95% CI, 1.29-3.12]) (table 2). Resistance to streptomycin was significantl associated with age, whereas resistance to isoniazid was not. The prevalence of resistance to streptomycin was significantl lower among patients у65 years old than among younger patients ( ). MDR was not associated with age, P p .024 sex, or urban/rural residence (table 2) .
Comparison of the results of the second survey (2001) with those of the firs (1996) showed a significan decrease in the prevalence of resistance to any drug (from 36.1% to 26.3%;
) and of resistance to streptomycin (from 29.4% to P ! .01 19.4%;
) among new patients. The prevalence of MDR P ! .01 also decreased (from 3.5% to 1.8%) during this period, but the difference was not significan (table 3) .
Repetition of the analysis without weighting for individual sampling probabilities for new patients in the 2001 survey changed the prevalence estimates for any resistance (26.8%), for streptomycin resistance (19.5%), and for MDR (2.3%) by 0.5% or less. It did not affect the results of the comparison with the 1996 survey.
DISCUSSION
In the south of Vietnam, the prevalence of drug resistance among new patients with smear-positive TB decreased during the period 1996-2001. The prevalence of MDR-TB also declined, but the decrease was not significant These finding indicate that the NTPV has managed to contain the emergence and spread of drug resistance, including MDR, and are consistent with the high cure rates (88.0% in 1996 and 91.8% in 2001) and low failure rates (1.7% in 1996 and 1.3% in 2001) reported for this part of the country (NTPV, unpublished data). This containment has been achieved by a DOTS program that does not include second-line treatment of patients with MDR-TB and in spite of several challenges to effective TB control: high levels of initial drug resistance to isoniazid and streptomycin [13] , an increasing contribution to TB treatment from the private sector [16] [17] [18] , and the spread of new M. tuberculosis strains, such as the Beijing genotype [24] .
The decrease in the prevalence of drug resistance since 1996 predominantly reflecte a decrease in resistance to streptomycin. This could be due to a natural decrease in the number of patients with reactivation TB who had been infected a long time ago when the uncontrolled use of streptomycin and isoniazid was widespread. However, initial resistance to streptomycin was least frequent in the oldest age group and most frequent in the youngest, suggesting a different explanation. One may be the role played by strain genotype. In a study of M. tuberculosis isolates mainly from the south of Vietnam, the Beijing genotype was associated both with drug resistance (notably to streptomycin) and with younger age, suggesting recent transmission [24] . Thus, recent selection and spread of Beijing strains could have resulted in a relative increase in the prevalence of streptomycin resistance that partly compensated for the decreasing prevalence due to the ageing of the patient population infected with streptomycin-resistant strains before 1975. Studies are under way to further explore the association between age, drug resistance, and genotype in Vietnam. Initial resistance to isoniazid and streptomycin was also more common in urban areas. This may reflec differences in the availability of these drugs on the free market and in the contribution of private health providers to TB treatment.
In the 1996 survey, resistance among previously treated patients was not assessed. In the 2001 survey, nearly two-thirds of the previously treated patients were infected with strains that were resistant to at least 1 drug, and nearly one-quarter were infected with MDR strains. Similar resistance levels were observed in recent studies in Ho Chi Minh City [14, 15] . The levels are consistent with high treatment adherence (i.e., a large proportion of patients who experienced treatment failure did so because of initial drug resistance) but also with the amplificatio of drug resistance via use of the 2SHRZ/6HE regimen in the presence of high initial levels of isoniazid and streptomycin resistance [12, 15] .
There are limitations to the present study. First, previous treatment of TB may have been missed-that is, previously treated patients may have been misclassifie as new patients. (The opposite, new patients being misclassifie as previously treated patients, may also have occurred but is less probable.)
The effect would be overestimation of drug resistance among new patients. However, a substantial effect on the trend estimates would be unlikely, because the proportion of previously treated patients reported by the NTPV has remained constant since 1995 [11] .
Second, the inclusion of part of the same clusters surveyed in 1996 and the variation in the numbers of specimens that were available for DST were reason for use of a weighed analysis based on individual sampling weights. Although in our view this analysis provides the best estimate from the available data, it is influence by clusters from which only a few specimens were tested. Although this had only a minimal effect on the estimates of the prevalence of drug resistance, it may have affected the representativeness of our survey sample.
We conclude that, in the south of Vietnam, the prevalence of drug resistance has significantl decreased and that levels of drug resistance, including MDR, among new patients with smear-positive TB have not increased during the past 6 years. This occurred despite high initial levels of resistance to isoniazid and streptomycin and despite the absence of second-line treatment. Although the availability of second-line treatment in a DOTS-Plus program is important from the perspective of an individual patient, a well-functioning DOTS program with high cure rates among new patients is apparently sufficien for containing MDR-TB in this setting.
